Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Cerebrospinal Fluid Profile of Amyloid β Peptides in Patients with Alzheimer’s Disease Determined by Protein Biochip Technology

Maddalena A.S.a · Papassotiropoulos A.a · Gonzalez-Agosti C.a · Signorell A.a · Hegi T.b · Pasch T.b · Nitsch R.M.a · Hock C.a

Author affiliations

aDivision of Psychiatry Research and bInstitute of Anesthesiology, University of Zürich, Zürich, Switzerland

Corresponding Author

Christoph Hock, MD

Division of Psychiatry Research

Psychiatric University Hospital Zürich, Lenggstrasse 31

CH–8029 Zürich (Switzerland)

Tel. +41 44 384 2271, Fax +41 44 384 2275, E-Mail chock@bli.unizh.ch

Related Articles for ""

Neurodegenerative Dis 2004;1:231–235

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Amyloid-β peptides (Aβ) are major components of amyloid plaques in the Alzheimer’s disease (AD) brain and have been proposed as diagnostic markers in cerebrospinal fluid (CSF). Aβ derived from brain may be processed into fragments before emerging in CSF. Therefore, we determined mass profiles of Aβ peptides in CSF of patients with AD and age-matched healthy control subjects (CTR) by using protein biochip technology. Aβ peptides were captured on the chip surfaces (spots) by the specific monoclonal antibody 6E10 and were then analyzed by integrated surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS). We found Aβ species with mean molecular masses at 1,583.3 Da (corresponding to Aβ2–14), 2,068.5 Da (Aβ1–17), 2,166.4 Da (Aβ1–18), 3,676.6 Da (Aβ1–33), 3,789.4 Da (Aβ1–34), 4,076.9 Da (Aβ1–37), 4,134.0 Da (Aβ1–38), 4,233.3 Da (Aβ1–39), 4,332.4 Da (Aβ1–40) and 4,516.8 Da (Aβ1–42) in both AD (n = 24) and CTR (n = 24) subjects. Aβ1–38 appeared to be a major Aβ species in human CSF along with Aβ1–40. Quantitation revealed that CSF levels of Aβ1–38 were significantly decreased in AD as compared to CTR subjects. The CSF profile of Aβ peptides may be used for diagnostic and therapeutic purposes in clinical studies.

© 2004 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: November 15, 2004
Issue release date: November 2004

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 1

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.